<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01669239</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI-1002</org_study_id>
    <secondary_id>2012-001201-24</secondary_id>
    <nct_id>NCT01669239</nct_id>
  </id_info>
  <brief_title>Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer</brief_title>
  <acronym>Opti-HER</acronym>
  <official_title>OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet®) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of
      neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients
      with HER2-positive breast cancer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of symptomatic (type A) and asymptomatic (type B) cardiac events during the study treatment period</measure>
    <time_frame>Following 12 months after first dose of the study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR in breast (pCRB)</measure>
    <time_frame>At the time of definitive surgery, an expected average of 23 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pCR in breast and axilla (pCRBA)</measure>
    <time_frame>At the time of definitive surgery, an expected average of 23 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical objective response rate (cORR) in the breast and axilla by RECIST criteria version 1.1</measure>
    <time_frame>At the time of definitive surgery, an expected average of 23 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Cancer Burden (RCB) at surgery following the procedures of the MD Anderson Cancer Center</measure>
    <time_frame>At the time of definitive surgery, an expected average of 23 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast conservation rate at surgery</measure>
    <time_frame>At the time of definitive surgery, an expected average of 23 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum biomarkers predictive of cardiotoxicity</measure>
    <time_frame>Following 12 months after first dose of the study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with grade 3/4 neutropenia (assessed by CTCAE v.4)</measure>
    <time_frame>Following 12 months after first dose of the study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of onset and time of recovery from symptomatic (type A) and asymptomatic (type B) cardiac events (assessed by CTCAE v.4)</measure>
    <time_frame>Following 12 months after first dose of the study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose reductions due to treatment toxicity (assessed by CTCAE v.4)</measure>
    <time_frame>Following 12 months after first dose of the study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose delays due to treatment toxicity (assessed by CTCAE v.4)</measure>
    <time_frame>Following 12 months after first dose of the study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events and serious adverse events (assessed by CTCAE v.4)</measure>
    <time_frame>Following 12 months after first dose of the study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Liposomal Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six cycles of:
Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks
Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks
Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks
Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin</intervention_name>
    <description>Six cycles of:
Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks
Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks
Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks
Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks</description>
    <arm_group_label>Liposomal Doxorubicin</arm_group_label>
    <other_name>Myocet® (liposome-encapsulated doxorubicin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent for all study procedures according to local regulatory
             requirements prior to beginning specific protocol procedures

          -  Female patients

          -  Age 18-74 years

          -  ECOG Performance Status of 0 or 1

          -  Histologically confirmed, untreated, invasive breast carcinoma stage II-IIIB

          -  Tumor size &gt; 2 cm by clinical or radiological assessment

          -  HER2+ invasive BC according to ASCO/CAP guidelines

          -  Known hormone receptor status or the possibility of its assessment

          -  Adequate organ function defined as:

               -  Absolute Neutrophil Count (ANC) ≥ 1.5 x 10**9/L

               -  Hemoglobin (Hgb) ≥ 9 g/dL

               -  Platelets &gt; 100 x 10**9/L

               -  Creatinine ≤ 1.6 mg/dL

               -  ALT and AST ≤ 2.5 x ULN

               -  Alkaline phosphatase ≤ 5 ULN

               -  Total bilirubin ≤ 1.5 mg/dL

          -  Baseline LVEF ≥ 55% measured by echocardiogram or MUGA scan

          -  Negative β-HCG pregnancy test (serum) for premenopausal women of reproductive capacity
             (those who are biologically capable of having children) and for women less than 12
             months after the menopause. All subjects who are biologically capable of having
             children must agree and commit to the use of a reliable method of birth control from 2
             weeks before administration of the first dose of investigational product until 28 days
             after the last dose of investigational product

          -  Absence of any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

        Exclusion Criteria:

          -  Clinical or radiologic evidence of metastatic disease at the time of study entry

          -  Prior chemotherapy, radiotherapy, or surgery for BC, other than excision of a tumor in
             the contralateral breast, and provided that the patient did not previously receive
             adjuvant radiotherapy or chemotherapy

          -  Subjects with a concurrently active second malignancy, other than adequately treated
             non melanoma skin cancers, in situ melanoma or in situ cervical cancer. Subjects with
             other non-mammary malignancies must have been disease-free for at least 5 years

          -  Known or suspected hypersensitivity reaction to any investigational or therapeutic
             compound or their incorporated substances

          -  Presence of CHF or LVEF &lt; 55%

          -  Clinically significant (i.e. active) cardiovascular disease, including cerebrovascular
             accident (&lt; 6 months before enrollment), unstable angina pectoris, myocardial
             infarction ≤ 6 months before enrollment, uncontrolled hypertension (systolic &gt; 150
             mmHg and/or diastolic &gt; 100 mmHg), or high-risk uncontrolled arrhythmias

          -  Uncontrolled diabetes mellitus, active peptic ulcer disease, or uncontrolled epilepsy

          -  Active uncontrolled infection at the time of enrolment

          -  History of significant co-morbidities that, in the judgment of the investigator, may
             interfere with the conduction of the study, the evaluation of response, or with
             informed consent

          -  Use of any investigational agent or participation in another therapeutic clinical
             trial concurrently or in the previous 30 days before the enrollment

          -  Patients who are pregnant or breast-feeding

          -  Women of child-bearing potential who are unable or unwilling to use acceptable
             contraceptive measures

          -  Inability or unwillingness to abide by the study protocol or cooperate fully with the
             investigator or designee
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquín Gavilá Gregori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro de Majadahonda</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sagrado Corazón USP</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gruposolti.org</url>
    <description>SOLTI Breast Cancer Research Group</description>
  </link>
  <reference>
    <citation>Gavilá J, Llombart A, Guerrero A, Ruíz A, Climent M, Guillem V. Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER2-positive breast cancer. Poster session presented at: 35th Annual San Antonio Breast Cancer Symposium (SABCS); 2012 December 4th-8th; San Antonio, Texas, United States.</citation>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2012</study_first_submitted>
  <study_first_submitted_qc>August 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Liposomal doxorubicin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Pertuzumab</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

